Enoxaparin Bioequivalence Study in Acute Coronary Syndrome Patients
Condition:   Acute Coronary Syndrome Interventions:   Drug: Lovenox;   Drug: Enoxaparin Sponsors:   University of Monastir;   University Hospital Fattouma Bourguiba Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials

Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial
AbstractObjectivesThe OVID study will demonstrate whether prophylactic-dose enoxaparin improves survival and reduces hospitalizations in symptomatic ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.Trial designThe OVID study is conducted as a multicentre open-label superiority randomised controlled trial.ParticipantsInclusion Criteria1. Signed patient informed consent after being fully informed about the study ’s background.2. Patients aged 50 years or older with a positive test for SARS-...
Source: Trials - September 9, 2020 Category: Research Source Type: clinical trials

Nebulized Heparin in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Conditions:   Covid19;   Pneumonia Interventions:   Drug: Heparin sodium;   Drug: Enoxaparin Sponsor:   Clinica San Camilo, Argentina Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2020 Category: Research Source Type: clinical trials

Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19
Conditions:   Covid19;   Pneumonia Interventions:   Drug: Heparin sodium;   Drug: Enoxaparin Sponsor:   Clinica San Camilo, Argentina Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2020 Category: Research Source Type: clinical trials

Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection
Conditions:   Covid19;   SARS-CoV Infection;   Pneumonia, Viral;   Coagulopathy Interventions:   Drug: Enoxaparin;   Drug: Methylprednisolone;   Drug: unfractionated heparin Sponsor:   Massimo Girardis Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 27, 2020 Category: Research Source Type: clinical trials

Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention
Condition:   Sars-CoV2 Interventions:   Drug: Lovenox 40 MG in 0.4 mL Prefilled Syringe;   Device: Ultrasound of the lower limbs Sponsors:   Centre Hospitalier Universitaire de Saint Etienne;   CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang Withdrawn (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 20, 2020 Category: Research Source Type: clinical trials

Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial
AbstractObjectivesTo assess the hypothesis that an adjunctive therapy with methylprednisolone and unfractionated heparin (UFH) or with methylprednisolone and low molecular weight heparin (LMWH) are more effective in reducing any-cause mortality in critically-ill ventilated patients with pneumonia from SARS-CoV-2 infection compared to LMWH alone.Trial designThe study is designed as a multi-centre, interventional, parallel group, superiority, randomized, investigator sponsored, three arms study. Patients, who satisfy all inclusion criteria and no exclusion criteria, will be randomly assigned to one of the three treatment gro...
Source: Trials - August 17, 2020 Category: Research Source Type: clinical trials

FREEDOM COVID Anticoagulation Strategy Randomized Trial
Conditions:   COVID-19;   SARS-CoV-2 Interventions:   Drug: Enoxaparin;   Drug: Apixaban Sponsor:   Valentin Fuster Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 13, 2020 Category: Research Source Type: clinical trials

FREEDOM COVID-19 Anticoagulation Strategy
Conditions:   COVID-19;   SARS-CoV-2 Interventions:   Drug: Enoxaparin;   Drug: Apixaban Sponsor:   Valentin Fuster Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 13, 2020 Category: Research Source Type: clinical trials